- Home
- SLDP vs CTMX Comparison
SLDP vs CTMX Comparison
Compare SLDP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- CTMX
- Stock Information
- Founded
- SLDP 2011
- CTMX 2008
- Country
- SLDP United States
- CTMX United States
- Employees
- SLDP N/A
- CTMX N/A
- Industry
- SLDP Electrical Products
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- CTMX Health Care
- Exchange
- SLDP Nasdaq
- CTMX Nasdaq
- Market Cap
- SLDP 645.4M
- CTMX 544.2M
- IPO Year
- SLDP N/A
- CTMX 2015
- Fundamental
- Price
- SLDP $6.06
- CTMX $3.32
- Analyst Decision
- SLDP Strong Buy
- CTMX Strong Buy
- Analyst Count
- SLDP 1
- CTMX 5
- Target Price
- SLDP $4.00
- CTMX $5.30
- AVG Volume (30 Days)
- SLDP 14.2M
- CTMX 4.3M
- Earning Date
- SLDP 11-06-2025
- CTMX 11-06-2025
- Dividend Yield
- SLDP N/A
- CTMX N/A
- EPS Growth
- SLDP N/A
- CTMX 263.20
- EPS
- SLDP N/A
- CTMX 0.49
- Revenue
- SLDP $22,667,000.00
- CTMX $141,100,000.00
- Revenue This Year
- SLDP $27.38
- CTMX N/A
- Revenue Next Year
- SLDP $37.97
- CTMX N/A
- P/E Ratio
- SLDP N/A
- CTMX $6.80
- Revenue Growth
- SLDP 14.83
- CTMX 18.01
- 52 Week Low
- SLDP $0.68
- CTMX $0.40
- 52 Week High
- SLDP $6.44
- CTMX $3.49
- Technical
- Relative Strength Index (RSI)
- SLDP 75.25
- CTMX 75.86
- Support Level
- SLDP $3.71
- CTMX $3.11
- Resistance Level
- SLDP $3.96
- CTMX $3.39
- Average True Range (ATR)
- SLDP 0.52
- CTMX 0.24
- MACD
- SLDP 0.23
- CTMX 0.10
- Stochastic Oscillator
- SLDP 95.40
- CTMX 90.91
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.